RxDoctor Payments Data

David Shelton, APRN

Family · Bardstown, KYNPI 1669442562

Payments from drug & device makers

$3,354in general payments, 2019–2025

Across 190 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$690
  • Boston Scientific$534
  • Novartis$523
  • E.r. Squibb & Sons, L.L.C.$435
  • Merck$260
  • Pfizer$196
  • plus $717 from 12 others

What the payments were for

  • Food & beverage$3,23496%
  • Education$1214%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,354 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$74,388
Medicare patients
568
Services billed
1,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban865$691,304
XareltoRivaroxaban137$108,794
EntrestoSacubitril/Valsartan107$99,197
Repatha SureclickEvolocumab102$65,803
BrilintaTicagrelor41$26,892
Praluent PenAlirocumab11$15,569
Metoprolol Succinate971$10,585
Valsartan341$6,571
Atorvastatin Calcium712$4,208
Diltiazem 24hr Er (Cd)Diltiazem Hcl123$3,235
Ranolazine ErRanolazine39$3,227
Bumetanide142$3,090
Potassium Chloride217$3,089
Amiodarone Hcl282$2,678
Isosorbide Mononitrate ErIsosorbide Mononitrate341$2,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$196$691,304865 claims
Johnson & JohnsonXarelto$101$108,794137 claims
NovartisEntresto$523$99,197107 claims
AstraZenecaBrilinta$159$26,89241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.

Other family in Bardstown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →